AstraZeneca On Tagrisso's Milestone Advance Into Adjuvant Lung Cancer
Executive Summary
Oncology business unit head David Fredrickson talked to Scrip about Tagrisso’s approval as the first targeted adjuvant treatment for patients who have NSCLC with EGFR mutations.
You may also be interested in...
J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
The (Non-COVID) Clinical Trial Hits And Misses Of 2020
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
AstraZeneca Sees SOURCE Tezepelumab Failure In Asthma
The SOURCE failure is a reversal for the novel Amgen-partnered TSLP inhibitor after NAVIGATOR success last month, and comes just days after the US FDA requested more analyses of the pivotal data for the kidney disease anemia therapy roxadustat.